Business
Cullinan is a biopharmaceutical company developing potential first- or best-in-class therapies for autoimmune diseases and cancer.
Cullinan's pipeline work consumed more cash as losses widened.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage immunology and oncologyNote
- Operating loss — ($241.6M), widerWatch
- Net loss — ($219.9M), widerWatch
- FCF — ($175.8M), weakerWatch
- Equity — $408.7M, -30.8%Watch
- Insiders — 8 purchases and 23 salesNote
- Accounting — FY2022 Altman safe; current EQ absentNote
Where the revenue comes from
Fiscal 2021, as Cullinan Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Pearl Zai Lab License Agreement$18.9M
Latest filings
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cullinan Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.